Rye Brook, N.Y., December 15, 2021 – The Food and Drug Administration (FDA) recently approved abatacept (Orencia), in combination with certain immunosuppressants, for the prevention of acute graft versus host disease (aGVHD) in patients 2 years and older who underwent a stem cell transplant from an unrelated donor.Read More
Largest Study to Date Demonstrates Most Blood Cancer Patients Benefit From a Third Primary Dose of mRNA COVID-19 VaccinePosted On: December 13, 2021
Study supports the Centers for Disease Control and Prevention (CDC) recommendation for immunocompromised adultsRead More
Rye Brook, N.Y., December 1, 2021 – The U.S. Food and Drug Administration (FDA) recently granted the seventh approval to daratumumab for the treatment of multiple myeloma. This injectable antibody is approved alone or in combination with other drugs at different states of multiple myeloma treatment.Read More
Rye Brook, N.Y., Nov. 19, 2021 — The Leukemia & Lymphoma Society applauds passage of critical patient-friendly reforms by the U.S. House of Representatives. The provisions, components of the Build Back Better Act, represent a key step towards ensuring millions of people — including cancer patients and survivors — have access to quality, affordable healthcare. LLS urges the U.S. Senate to pass these policies without delay.Read More
Rye Brook, N.Y., November 16, 2021 – The U.S. Food and Drug Administration (FDA) last week announced approval of ropeginterferon alfa-2b-njft (ropeg, BESREMi®) for the treatment of polycythemia vera (PV). This is the first medication approved for PV that patients can take regardless of their treatment history, meaning it can be used to treat this rare form of cancer early, which may help reduce the risk of progression over time.
Rye Brook, N.Y., November 11, 2021 – The U.S. Food and Drug Administration (FDA) recently granted accelerated approval to asciminib (Scemblix®) for patients with Philadelphia chromosome-positive chronic myeloid leukemia chronic phase (Ph+ CML-CP) who did not tolerate or had inadequate response to treatment with tyrosine kinase inhibitors (TKIs). FDA also approved asciminib to treat adult patients with Ph+ CML-CP with the T315I mutation.
Rye Brook, N.Y., October 18, 2021 – LLS mourns the passing of Colin Powell. His death is a reminder of the seriousness of the pandemic and the ongoing need to protect the most vulnerable in our society.Read More
Please send all media-related inquiries and interview requests to email@example.com. An LLS representative will respond as soon as possible.